9 Meters Biopharma, Inc.

OTC: NMTRQ · Healthcare · Biotechnology

PublicHQ Raleigh, NC · WakeCIK 0001551986Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 27

v0.1 · 5/100 weight · pillars only

↑ listing tenure, balance-sheet leverage · ↓ return on equity, market scale

Methodology →

Revenue TTM

—

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$43.8M

Employees

as of 2026-08-03

Market cap

$1.4k

as of 2026-08-03

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$43.8M-$43.8M2022

Operating income-$42.0M-$42.0M2022

Total assets$33.1M$33.1M2022

Liabilities$30.7M$30.7M2022

Equity$2.4M$2.4M2022

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is 9 Meters Biopharma, Inc.’s financial profile?

9 Meters Biopharma, Inc. earned -$43.8M in FY2022 net income.

Peers · Healthcare

Redwood Scientific Technologies, Inc.——Juva Life Inc.——Assure Holdings Corp.——MSP Recovery, Inc.——PsyBio Therapeutics Corp——FusionPharm, Inc.——

Neighbors

Wake →

Martin Marietta Materials, Inc.$6.2B80B+First Citizens BancShares, Inc.$9.5B50D Liquidia Corporation$158.3M59C Ralliant Corp$2.1B40D Enact Holdings Inc.$1.2B67B Vontier Corporation$3.1B66B

Key facts

CEOPeter H. R. Green

SectorHealthcare

IndustryBiotechnology

HeadquartersRaleigh, NC

ExchangeOTC: NMTRQ

Employees10

IPO date2016-07-08

Latest filings

8-K2023-07-18 8-K2023-06-16 8-K2023-05-30 8-K2023-05-22 8-K2023-05-19 8-K2023-05-15 10-Q2023-05-15 8-K2023-04-27

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.